following an abbreviated submission
adalimumab (Humira®) solution for injection is accepted for restricted use within NHS Scotland.
Indication under review: in combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 2 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in children aged less than 2 years.
SMC restriction: use within specialist rheumatology services (including those working within the network for paediatric rheumatology). Combination treatment with methotrexate is the primary option. Doses in this age group are based on body surface area calculations.
The Scottish Medicines Consortium has previously accepted this product for restricted use for this indication in children and adolescents aged 4 to 17 years.
Download detailed advice78KB (PDF)
Medicine details
- Medicine name:
- adalimumab (Humira)
- SMC ID:
- 881/13
- Indication:
- In combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 2 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in children aged less than 2 years.
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Abbreviated
- Status
- Superseded
- Date advice published
- 08 July 2013